---
title: "Novartis rises 5% in regular trading as Q2 earnings beat estimates"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293356053.md"
description: "Novartis climbs 5% during regular trading after Q2 core EPS and sales top forecasts, driven by strong innovation drug demand."
datetime: "2026-07-21T14:21:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293356053.md)
  - [en](https://longbridge.com/en/news/293356053.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293356053.md)
generator: "portal-rs"
---

# Novartis rises 5% in regular trading as Q2 earnings beat estimates

诺华制药 (NVS.US) 盘中涨 4.55%，现报 156.365 美元。

消息面上，诺华公布第二季度业绩超预期，核心每股收益**2.41 美元**，高于市场预期的**2.16 美元**；净销售额**144.1 亿美元**，超出预期的**139.4 亿美元**。Kisqali 和 Kesimpta 等创新药需求强劲，抵消了 Entresto 等药物面临仿制药竞争的影响。

公司重申 2026 年全年净销售额低个位数增长指引。首席执行官在电话会议中表示，公司将继续寻求收购机会，尤其青睐 20 亿美元以下的标的。展望下半年，公司预计将迎来多项重要数据读出，目前进展符合预期。

### Related Stocks

- [NVS.US](https://longbridge.com/en/quote/NVS.US.md)

## Related News & Research

- [Boston Common Asset Management LLC Cuts Stock Position in Novartis AG $NVS](https://longbridge.com/en/news/295901586.md)
- [D.A. Davidson & CO. Lowers Position in Novartis AG $NVS](https://longbridge.com/en/news/295995683.md)
- [Novartis defeats UK court bid to invalidate blockbuster drug Entresto patent](https://longbridge.com/en/news/295810760.md)
- [Advisors Capital Management LLC Takes Position in Gilead Sciences, Inc. $GILD](https://longbridge.com/en/news/296674916.md)
- [How Investors Are Reacting To Zoetis (ZTS) Cut Guidance Flat Q2 Results And New FDA EUA](https://longbridge.com/en/news/296250302.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**